{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:22:11Z","timestamp":1787775731628,"version":"build-2784847793"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Tuberculosis (TB) is a leading cause of death in patients with human immunodeficiency virus (HIV)\/AIDS. About 60% of HIV-positive individuals with latent TB infection (LTBI) develop active TB. Isoniazid preventive therapy (IPT) is recommended by the World Health Organization to prevent the progression of active TB in people living with HIV\/AIDS (PLWHA). However, IPT implementation has been limited in some countries like Indonesia. The objective of this study was to assess the effect of IPT administration on the incidence of active TB in HIV patients with latent TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This was a quasi-experimental prospective cohort study conducted in an academic hospital in Indonesia. Interferon-gamma release assay-positive HIV-TB patients were randomly divided into an IPT group (received 6 months of IPT) and a non-IPT group. The incidence of active pulmonary TB was compared between the two groups after 6 months of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 23 eligible patients, 22 were enrolled (10 in the IPT group, 12 in the non-IPT group). The incidence of active pulmonary TB was 0% in both groups. Factors associated with the absence of TB in both groups were the use of antiretroviral therapy for &gt;4 years and a CD4+ T lymphocyte count &gt;200 cells\/\u03bcL. IPT was found to be safe with minimal adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this setting, the use of long-term antiretroviral therapy and higher CD4+ counts, rather than just IPT, were the key factors associated with preventing active TB in latent HIV-TB patients. These findings suggest that comprehensive HIV management may be more important than IPT alone for TB control in PLWHA. Further research is needed to optimize TB prevention strategies in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_146_24","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:00:07Z","timestamp":1726416007000},"page":"293-298","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Factors Associated with Absence of Active Pulmonary Tuberculosis in HIV Patients with Latent Tuberculosis, Beyond Isoniazid Preventive Therapy"],"prefix":"10.4103","volume":"13","author":[{"given":"Shinta Karina","family":"Yuniati","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tutik","family":"Kusmiati","sequence":"additional","affiliation":[{"name":"Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"R2-20241212","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4103\/ijmy.ijmy_164_22","article-title":"Coexistence of human immunodeficiency virus, active pulmonary tuberculosis, and aspergilloma: A rare entity","volume":"11","author":"Leo","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"R3-20241212","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijmy.ijmy_140_18","article-title":"Associated factors with unsuccessful tuberculosis treatment outcomes among tuberculosis\/HIV coinfected patients with drug-resistant tuberculosis","volume":"7","author":"Azeez","year":"2018","journal-title":"Int J Mycobacteriol"},{"key":"R4-20241212","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/bbrj.bbrj_50_19","article-title":"Coinfection between human immunodeficiency virus and tuberculosis: A consideration on ritonavir-related heme oxygenase-1 pathway","volume":"3","author":"Sriwijitalai","year":"2019","journal-title":"Biomed Biotechnol Res J"},{"key":"R5-20241212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/jpdtsm.jpdtsm_48_22","article-title":"Factor associated with treatment noncompletion during implementation of isoniazid-preventive therapy in ten pilot sites of Lome, Togo","volume":"1","author":"Biaou","year":"2022","journal-title":"J Prev Diagn Treat Strategies Med"},{"key":"R6-20241212","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/ijerph20010621","article-title":"Isoniazid preventive therapy for prevention of tuberculosis among people living with HIV in Ethiopia: A systematic review of implementation and impacts","volume":"20","author":"Assefa","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R8-20241212","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4103\/jgid.jgid_138_18","article-title":"Implementation of isoniazid preventive therapy among people living with HIV in Northwestern Nigeria: Completion rate and predictive factors","volume":"12","author":"Adepoju","year":"2020","journal-title":"J Glob Infect Dis"},{"key":"R9-20241212","first-page":"20","article-title":"Barriers to the implementation of isoniazid preventive therapy among children under five years old in close contact with sputum smear-positive TB patients","volume":"10","author":"Nugroho","year":"2021","journal-title":"Diponegoro Med J"},{"key":"R10-20241212","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/ijph.ijph_206_23","article-title":"Assessment of isoniazid preventive therapy and incidence of tuberculosis among people living with human immunodeficiency virus seeking care in an anti-retroviral therapy center, Puducherry","volume":"68","author":"Kannusamy","year":"2024","journal-title":"Indian J Public Health"},{"key":"R11-20241212","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.3346\/jkms.2019.34.e259","article-title":"Good agreement between an interferon gamma release assay and tuberculin skin tests in testing for latent tuberculosis infection among HIV-infected patients in Indonesia","volume":"34","author":"Reviono","year":"2019","journal-title":"J Korean Med Sci"},{"key":"R12-20241212","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.3390\/ijerph20054556","article-title":"Efficacy and risk factors of interferon-gamma release assays among HIV-positive individuals","volume":"20","author":"Qin","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R13-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00442-2021","article-title":"Latent tuberculosis screening and treatment in HIV: Highly acceptable in a prospective cohort study","volume":"8","author":"White","year":"2022","journal-title":"ERJ Open Res"},{"key":"R15-20241212","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/bbrj.bbrj_72_17","article-title":"High rates of human immunodeficiency virus and drug resistance in tuberculosis patients in Manila, Philippines","volume":"1","author":"Solante","year":"2017","journal-title":"Biomed Biotechnol Res J"},{"key":"R16-20241212","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/v16030321","article-title":"HIV-TB coinfection: Current therapeutic approaches and drug interactions","volume":"16","author":"Navasardyan","year":"2024","journal-title":"Viruses"},{"key":"R17-20241212","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijid.2020.03.011","article-title":"Historical review of studies on the effect of treating latent tuberculosis","volume":"92S","author":"M\u00f8lhave","year":"2020","journal-title":"Int J Infect Dis"},{"key":"R18-20241212","doi-asserted-by":"crossref","first-page":"e0223076","DOI":"10.1371\/journal.pone.0223076","article-title":"Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe","volume":"14","author":"Nyathi","year":"2019","journal-title":"PLoS One"},{"key":"R19-20241212","doi-asserted-by":"crossref","first-page":"e0266285","DOI":"10.1371\/journal.pone.0266285","article-title":"Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study","volume":"17","author":"Kazibwe","year":"2022","journal-title":"PLoS One"},{"key":"R20-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11908-020-00726-x","article-title":"Latent tuberculosis and HIV infection","volume":"22","author":"Bares","year":"2020","journal-title":"Curr Infect Dis Rep"},{"key":"R21-20241212","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.3390\/ijms21228854","article-title":"Addressing latent tuberculosis: New advances in mimicking the disease, discovering key targets, and designing hit compounds","volume":"21","author":"Campani\u00e7o","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R22-20241212","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4103\/ijmr.IJMR_1582_18","article-title":"Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting","volume":"152","author":"Padmapriyadarsini","year":"2020","journal-title":"Indian J Med Res"},{"key":"R23-20241212","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAD.0000000000003747","article-title":"Screening for tuberculosis infection and effectiveness of preventive treatment among people with HIV in low-incidence settings","volume":"38","author":"van","year":"2024","journal-title":"AIDS"},{"key":"R24-20241212","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5588\/ijtld.18.0207","article-title":"Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries","volume":"23","author":"Harries","year":"2019","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_146_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:40:28Z","timestamp":1787773228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_146_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_146_24","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-06-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}